FDA Draft Guidance Could Change How Sponsors Plan Individualized Gene-Editing Therapies

By Elizabeth Urbanek, Executive Editor

The U.S. Food and Drug Administration (FDA) has proposed a regulatory framework that could allow sponsors to include multiple versions of certain individualized gene-editing therapies in a single biologics license application (BLA). The draft guidance, issued October 27, describes how sponsors could define acceptable differences between product variants and demonstrate their safety and potency.

The proposal focuses on therapies designed to address different genetic variants associated with the same single-gene disease. Instead of submit a separate application for every version, sponsors could establish boundaries for the variations covered by one application.

For clinical supply, those differences matter. Sponsors will need to consider how each difference affects manufacturing, labeling, and the documentation required for each variant.

The FDA is accepting public comments on the draft through November 27, 2026.

What This Means For Clinical Supply

The draft introduces the concept of an individualized feature space (IFS), which defines the range of variation a therapy can accommodate. Sponsors would need scientific evidence to support those boundaries, including data on how changes to gene-editing components could affect the product.

A new variant that falls within an established IFS could potentially be managed as a manufacturing change rather than through an entirely separate product application. Sponsors would still need evidence to support the variant's safety and activity, and the FDA would assess the proposed approach on a case-by-case basis.

For clinical supply teams, that raises practical questions about how product variations will be handled as a program develops.

• Manufacturing and process controls: Which product characteristics can change, and which need to remain consistent? The answer affects manufacturing processes, validation and documentation.
• Product identification and labeling: How will teams distinguish variants and ensure the correct product and documentation reach the intended clinical site?
• Supply planning: If a program adds variants over time, how will sponsors account for manufacturing needs and product availability?
• Change management: What evidence will be needed to support a new variant, and how will manufacturing, quality and regulatory teams document and manage the change?

The Supply Question

When should clinical supply teams be involved in planning for individualized therapies?

Related Clinical Supply Leader Editorials

• What Advanced Therapy Logistics Actually Need From Patient-Specific Supply Models
• How To Build Clinical Supply Into Drug Development From The Start

About The Author:

Elizabeth Urbanek is the Executive Editor of Clinical Supply Leader, where she works with clinical trial supply and logistics professionals to bring real-world perspectives and operational challenges to the field.

Before joining life sciences media, Elizabeth spent more than 15 years in broadcast, digital and live-event storytelling, helping highly technical teams communicate complex ideas with clarity and impact. She brings that same approach to clinical supply, creating editorial space for experts to share what is happening across clinical trial operations.

Elizabeth is passionate about connecting people and ideas, identifying emerging themes and showcasing work that can move the clinical supply field forward.